TOP > 外国特許検索 > PROPHYLACTIC/THERAPEUTIC AGENT FOR ARTHRITIS, TEST KIT FOR ARTHRITIS, AND METHOD FOR SCREENING FOR PROPHYLACTIC/THERAPEUTIC AGENT FOR ARTHRITIS

PROPHYLACTIC/THERAPEUTIC AGENT FOR ARTHRITIS, TEST KIT FOR ARTHRITIS, AND METHOD FOR SCREENING FOR PROPHYLACTIC/THERAPEUTIC AGENT FOR ARTHRITIS

外国特許コード F160008755
整理番号 (S2014-1467-N0)
掲載日 2016年6月2日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP074556
国際公開番号 WO 2016031996
国際出願日 平成27年8月24日(2015.8.24)
国際公開日 平成28年3月3日(2016.3.3)
優先権データ
  • 特願2014-174638 (2014.8.28) JP
発明の名称 (英語) PROPHYLACTIC/THERAPEUTIC AGENT FOR ARTHRITIS, TEST KIT FOR ARTHRITIS, AND METHOD FOR SCREENING FOR PROPHYLACTIC/THERAPEUTIC AGENT FOR ARTHRITIS
発明の概要(英語) The present invention provides: a prophylactic/therapeutic agent for arthritis including rheumatoid arthritis, which comprises a Tet3 expression inhibitor; a kit for diagnosing arthritis including rheumatoid arthritis; and a means for searching for a novel substance having a prophylactic and/or therapeutic activity on arthritis including rheumatoid arthritis.
従来技術、競合技術の概要(英語) BACKGROUND ART
Is rheumatoid arthritis, systemic chronic inflammation at a joint of the refractory autoimmune disease occurs. Proliferation of synovial tissue within the joint, cartilage and bone destruction and increased progressively. Rheumatoid arthritis synovial fibroblasts is stimulated by macrophage and lymphocyte (FLS) (TNF α, to inflammatory cytokines IL-1β) is activated, the activated synovial fibroblasts, inflammatory cytokine or chemokine production, on the other hand cause joint destruction by matrix degradation enzyme secretion, proliferation, enhancement of the invasive potential, such as a reduction in apoptosis-sensitive cancer cells also have similar properties. In recent years, as a result of GWAS (Genome-Wide Association Study) of genetic polymorphisms of about 30 and the development of rheumatoid arthritis severity involves has become known. On the other hand, the development of abnormal HDAC and severity of rheumatoid arthritis as suggested involves deep becomes. DNA methylation of one of the exemplary mechanisms HDAC, the entire genome in rheumatoid arthritis, or specific promoter region of the gene of which there is an abnormality DNA methylation has been reported. The inventors have recently, genome DNA methylation analysis by exhaustive, synovial fibroblasts derived from patients with rheumatoid arthritis disease specific to the DNA methylation pattern is present, the aberrant methylation of a gene involved in the pathology of rheumatoid arthritis many deep (non-patent document 1) indicated. Biological formulations targeted inflammatory cytokines rheumatoid arthritis treatment, but the induction of remission in a familiar to those, the treatment of rheumatoid arthritis is a so-called 'Window of Opportunity' is present, the delay of onset of the therapeutic effect as the same time. This is, the duration of the inflammatory environment itself, present at the site of inflammation in the synovial membrane cells and more aggressive treatment-resistant depression are altered to phenotype suggests the possibility that, although the detailed mechanism was unknown in. The inventors, synovial inflammation in rheumatoid arthritis, osteoarthritis and plays a pivotal role destruction IL-1β TNF α is, in methylation enzymes DNA FLS (DNMT) and decreased the expression of, promotes passive demethylation shown in, disease-specific DNA methylation patterns in one end of the molecular mechanism of formed (non-patent document 2) revealed. However, it is an active DNA demethylation was unknown mechanism for, methylated DNA, picture of the dynamism of the demethylation was unknown. In recent years, demethylated DNA Tet (Ten-Eleven translocation) that functions as an enzyme family of proteins identified, 5 - methylcytosine (5mC) Tet protein 5 - (5hmC) and hydroxide synthesized hydroxycytosine reported, such as DNA methylation in ES cells rapidly dynamism studies show their evolution. However, more of the activities of Tet in rheumatoid arthritis has still not been revealed, treating rheumatoid arthritis Tet protein can be targeted at all whether or not it was still unknown.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH, JAPAN
  • 発明者(英語)
  • NAKANO, Kazuhisa
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close